References
- Logie A, Dunois-Larde C, Rosty C et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum. Mol. Genet.14(9), 1153–1160 (2005).
- Hafner C, van Oers JM, Vogt T et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J. Clin. Invest.116(8), 2201–2207 (2006).
- Cappellen D, De Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet.23(1), 18–20 (1999).
- Vajo Z, Francomano CA, Wilkin DJ. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr. Rev.21(1), 23–39 (2000).
- Happle R. Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin. J. Am. Acad. Dermatol.16(4), 899–906 (1987).
- Naski MC, Wang Q, Xu J, Ornitz DM. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat. Genet.13(2), 233–237 (1996).
- L’Hote CG, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp. Cell Res.304(2), 417–431 (2005).
- Hafner C, van Oers JM, Hartmann A et al. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J. Invest. Dermatol.116(8), 2201–2207 (2006).
- Lopez-Knowles E, Hernandez S, Malats N et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res.66(15), 7401–7404 (2006).
- Chen J, Lee BH, Williams IR et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene24(56), 8259–8267 (2005).
- Trudel S, Ely S, Farooqi Y et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood103(9), 3521–3528 (2004).